PAINREFORM LTD PRFX 深 滬
等待開盤 10-29 09:30:00 美东时间
1.31
-0.010
-0.76%
華盛通- 最 高1.34
- 今 開1.29
- 成交量 3.64万股
- 最 低 1.28
- 昨 收 1.32
- 總市值 263.72万
- 52周最高 16.63
- 市盈率 靜 --
- 換手率 1.81%
- 52周最低 1.20
- 委 比 -60.00%
- 總股本 201.31万
- 歷史最高 1884.00
- 量 比 0.40
- 振 幅 4.55%
- 歷史最低 1.20
- 每 手 1
- 風險率 0.99%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多PainReform Provides Business Update for the Six Months Ended June 30, 2025
PainReform Ltd. reported progress in its dual strategy to reformulate therapeutics and develop AI-driven solar technologies. The company completed a majority investment in LayerBio, acquiring its OcuRing™-K, a dropless cataract therapy targeting a $9B market. PainReform advanced PRF-110, showing early efficacy in postoperative pain, while spending on R&D fell to $0.3M. DeepSolar expanded with a Smart Energy Management app, joined NVIDIA's Connect...
10-01 13:27
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) rose sharply in pre-market...
08-20 19:24
PainReform/DeepSolar Accepted into NVIDIA Connect Program
DeepSolar, a business unit of PainReform, has been accepted into NVIDIA's Connect Program to enhance its AI-driven solar forecasting platform, DeepSolar Predict, improving weather forecast accuracy by up to 50% and optimizing energy asset performance. This collaboration aims to address critical industry needs, including reducing imbalance penalties, maximizing revenue through better energy timing, and strengthening grid stability. The program pro...
08-19 12:30
PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System
PainReform Ltd. has acquired a majority stake in LayerBio Inc., a biotech company developing "dropless" solutions for ophthalmic surgery. The investment focuses on advancing LayerBio’s OcuRing™-K, a sustained-release intraocular ring designed to deliver anti-inflammatory and analgesic medication during cataract surgery, addressing patient compliance issues and reducing reliance on multiple medications. This transaction positions PainReform to add...
08-13 12:30
PainReform Signs Strategic Investment Agreement With LayerBio To Expand Non-Opiate Pain Management Pipeline Into Opthamology
PainReform Ltd. (NASDAQ:PRFX), today announced, through its pharmaceutical division, the signing of a strategic investment agreement with LayerBio Inc., a privately held Boston biotechnology company developing
07-10 20:38
PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio
PainReform Ltd. (Nasdaq: PRFX) has entered a strategic investment agreement with LayerBio Inc., a Boston-based biotech company, to expand into ophthalmology. PainReform will acquire a majority stake in LayerBio and sit on its board, in exchange for a $3 million investment tied to milestones. LayerBio’s OcuRing-K, a sustained-release intraocular ring, aims to replace traditional post-cataract eye drops, targeting the 3 million annual U.S. cataract...
07-10 12:30
Market-Moving News for May 8th
SEZL: 39% | Sezzle Shares Are Trading Higher After The Company Reported Better Then Expected Q1 EPS And Sales LZ: 18% | LegalZoom.com shares are trading higher after the company reported
05-08 19:17
PainReform shares are trading higher after the company announced it launched a strategic AI pilot with Econergy Renewable Energy.
PainReform shares are trading higher after the company announced it launched a ...
05-08 04:33
PainReform Regains Nasdaq Compliance as of April 16, 2025
PainReform ( ($PRFX) ) has provided an update. On April 16, 2025, PainReform Lt...
04-18 05:30
PainReform Moves Towards Nasdaq Compliance with Strategic Acquisition
PainReform ( ($PRFX) ) has provided an announcement. PainReform Ltd. announced ...
04-12 05:57
